ArticleBrain tumor research and treatment2025
MicroRNA Expression and Neurocognitive Outcomes in Children and Young People With Primary Brain Tumor in Karachi, Pakistan: A Pilot Exploratory Study.
Article in Brain tumor research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundmicroRNAs regulate various cellular pathways and may serve as medium-term prognostic markers in neurocognitive function, as suggested by adult studies. However, no comparable data exist for children with central nervous system tumors. This pilot study explored miRNA expression and its correlation with 12-month posttreatment neurocognitive function in children and young adults (5-21 years) with primary brain tumors.
methodsThe study was conducted at Aga Khan University Hospital and Jinnah Postgraduate Medical Center (November 2020 to July 2023). This study analyzed serum levels of miR-21, miR-146a, miR-296-5p, miR-210, and miR-10b using reverse transcriptase quantitative PCR. Neurocognitive assessments using Slosson Intelligence Test, Raven's Progressive Matrices, and Wechsler Intelligence Scale were performed at pretreatment and 12 months posttreatment. The paired t-test was used to assess miRNA expressions, and correlation analysis assessed relationships between pretreatment miRNA expression and neurocognitive outcomes.
resultsOf the 48 patients, serum samples were available for analysis from 34 (71%) patients each at pretreatment and 48 hours post-surgery, and 13 (27%) patients at 12 months posttreatment. A statistically significant negative correlation was found between pretreatment miR-210 levels and perceptual reasoning scores at 12 months posttreatment (ρ=-0.59), and a positive correlation between pretreatment miR-10b levels and processing speed scores (ρ=0.49). However, there were no differences in microRNA expressions between pretreatment and 48 hours post-surgery (n=34), pretreatment and 12 months posttreatment (n=13), or 48 hours post-surgery and 12 months posttreatment.
conclusionThis pilot exploratory study found two statistically significant correlations: a negative correlation between pretreatment miR-210 levels and 12 months posttreatment perceptual reasoning scores and a positive correlation between miR-10b expression and 12 months posttreatment speed scores. Further studies are needed to understand the protective or restorative function of miR-10b in cognitive processes and the detrimental role of miR-210 in cognitive processes to evaluate their potential future use as prognostic biomarkers for neurocognitive outcomes in children and young people with primary brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.